<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829413</url>
  </required_header>
  <id_info>
    <org_study_id>BR1-130</org_study_id>
    <nct_id>NCT00829413</nct_id>
  </id_info>
  <brief_title>SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization</brief_title>
  <official_title>Characterization Of Focal Liver Lesions With Sonovue®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Unenhanced Ultrasound Imaging Using Histology Or Combined Imaging/Clinical Data As Truth Standard</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the Sensitivity and Specificity of
      SonoVue®-enhanced ultrasound is superior to that of unenhanced ultrasound for the
      characterization of benign versus malignant FLLs using final diagnosis based on histology or
      combined imaging (CE-CT and/or CE MRI)/clinical data as truth standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unit of analysis for the outcome measures was the lesion, equivalent to the subject, since
      each subject had a single lesion that was to be characterized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs) using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-diagnose (ITD) population. Unit of analysis was the lesion, equivalent to subject, since each subject had a single lesion to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and/or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard'</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Among the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy: Percentage of True Positive and True Negative Among All Lesions</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value [PPV]: Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up.
Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value [NPV]: Percentage of True Negative Lesions Among All Benign Lesions Per Ultrasound</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Diagnosis of Malignant FLLs</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific Diagnosis of Benign FLLs</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Among the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-reader Agreement</measure>
    <time_frame>24 hours to 6 months</time_frame>
    <description>Kappa statistic based on assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately and computation for the percentage agreement within two categories: &quot;3 out of 3 readers agree&quot; and &quot;2 out of 3 readers agree&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">353</enrollment>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Patients who received SonoVue</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with at least one target lesions requiring work-up for characterization to undergo
Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;
SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and
Truth standard
2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SonoVue®</intervention_name>
    <description>SonoVue (2.4 mL)</description>
    <arm_group_label>Patients who received SonoVue</arm_group_label>
    <other_name>sulfur hexafluoride microbubbles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female.

          -  Provides written Informed Consent and is willing to comply with protocol requirements.

          -  Is at least 18 years of age.

          -  Has at least 1 FLL (target lesion) requiring work-up for characterization. Target
             lesions may include those:

        Incidentally detected, In subjects with chronic hepatitis or liver cirrhosis, In subjects
        with known history of malignancy.

          -  Is scheduled for surgical removal or biopsy of the target lesion from 24 hours to 30
             days after the SonoVue® administration OR

          -  In case tissue biopsy is not indicated nor surgery planned, is scheduled for or has
             performed a CE-CT and/or CE-MRI of the target lesion from 30 days to 48 hours prior to
             or from 24 hours to 30 days after the administration of SonoVue®.

        Exclusion Criteria:

          -  Has an acoustic window insufficient for adequate ultrasound examination of the liver.

          -  Has a FLL that cannot be identified with unenhanced ultrasound.

          -  Has received or is scheduled for antineoplastic chemotherapy or an invasive procedure
             in the time period between test procedures and truth standard assessments which may
             have modified the target lesion.

          -  Is receiving any other contrast medium, within the 48 hours before and up to 24 hours
             following the administration of SonoVue®.

          -  Has previously been enrolled in and completed this study.

          -  Known right to left cardiac shunt, bidirectional or transient.

          -  Has any known allergy to 1 or more of the ingredients of the investigational product
             (sulfur hexafluoride or to any components of SonoVue®).

          -  Has any contraindication to 1 of the planned imaging procedures (ultrasound, CT or
             MRI), e.g., implants, claustrophobia, inadequate medical conditions etc.

          -  Has received an investigational compound within 30 days before admission into this
             study.

          -  Has any medical condition or other circumstances which would significantly decrease
             the chances of obtaining reliable data, achieving study objectives, or completing the
             study and/or post-dose follow-up examinations.

          -  Is determined by the Investigator that the subject is clinically unsuitable for the
             study.

          -  Is a pregnant or lactating female. Exclude the possibility of pregnancy by:

        testing on site at the institution serum βHCG within 24 hours prior to the start of
        SonoVue® administration, surgical history (e.g., tubal ligation or hysterectomy), post
        menopausal with a minimum 1 year without menses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Spinazzi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bracco Diagnostics Inc.</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>July 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2018</results_first_posted>
  <disposition_first_submitted>August 18, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2014</disposition_first_posted>
  <last_update_submitted>July 5, 2018</last_update_submitted>
  <last_update_submitted_qc>July 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Initiation Date (first subject enrolled): 15 June 2010; Study completion date (last patient completed study related activities): 18 February 2013. The study was conducted at 18 investigational sites; 11 sites throughout the United States (USA), 5 sites in Europe, and 2 sites in Canada.</recruitment_details>
      <pre_assignment_details>A total of 67 patients received SonoVue in the training phase and were included only in safety population. A total of 259 patients received SonoVue in the efficacy phase. The 67 patients, included within the &quot;Not Completed&quot; category below, are the training patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Safety Population</title>
          <description>Interventions included SonoVue administration, unenhanced (UE-US) and SonoVue-enhanced ultrasound (CE-US) and definitive truth standard diagnosis.
Any patient who received SonoVue is included in the Safety Population. Thirteen patients who started had &quot;No study drug administered&quot; and are not included in the Safety Population.
Among patients in the Safety Population, 67 training phase patients were excluded from efficacy analysis. Completed patients included efficacy phase patients who underwent unenhanced and SonoVue-enhanced ultrasound and had definite truth standard diagnosis available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No study drug admimnistered</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Training Patients</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No truth standard procedure available</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technically inadequate truth standard</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Indeterminate diagnosis from truth stand</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ITD Population</title>
          <description>All patients who were enrolled in the efficacy phase, received SonoVue, had a definite final diagnosis from truth standard and unenhanced and SonoVue-enhanced ultrasonography available</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="259"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard</title>
        <description>Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs) using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-diagnose (ITD) population. Unit of analysis was the lesion, equivalent to subject, since each subject had a single lesion to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and/or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among 259 ITD subjects, 119 were malignant by truth standard and were included for sensitivity.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard</title>
          <description>Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs) using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-diagnose (ITD) population. Unit of analysis was the lesion, equivalent to subject, since each subject had a single lesion to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.
Truth standard: CE-CT and/or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100</description>
          <population>Among 259 ITD subjects, 119 were malignant by truth standard and were included for sensitivity.</population>
          <units>Percentage of true positive lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Malignant lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="119"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Malignant lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="119"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" lower_limit="39.8" upper_limit="57.7"/>
                    <measurement group_id="O2" value="86.6" lower_limit="80.4" upper_limit="92.7"/>
                    <measurement group_id="O3" value="35.3" lower_limit="26.7" upper_limit="43.9"/>
                    <measurement group_id="O4" value="75.6" lower_limit="67.9" upper_limit="83.3"/>
                    <measurement group_id="O5" value="16.0" lower_limit="9.4" upper_limit="22.5"/>
                    <measurement group_id="O6" value="91.6" lower_limit="86.6" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Sensitivity (%)</param_type>
            <param_value>37.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.4</ci_lower_limit>
            <ci_upper_limit>48.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Sensitivity (%)</param_type>
            <param_value>40.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.4</ci_lower_limit>
            <ci_upper_limit>50.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Sensitivity (%)</param_type>
            <param_value>75.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.9</ci_lower_limit>
            <ci_upper_limit>83.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard'</title>
        <description>Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Among the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard and were were included for specificty.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard'</title>
          <description>Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Among the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.</description>
          <population>Among the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard and were were included for specificty.</population>
          <units>Percentage of true benign lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Benign lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Benign lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" lower_limit="54.9" upper_limit="70.9"/>
                    <measurement group_id="O2" value="70.7" lower_limit="63.2" upper_limit="78.3"/>
                    <measurement group_id="O3" value="54.3" lower_limit="46.0" upper_limit="62.5"/>
                    <measurement group_id="O4" value="82.9" lower_limit="76.6" upper_limit="89.1"/>
                    <measurement group_id="O5" value="22.1" lower_limit="15.3" upper_limit="29.0"/>
                    <measurement group_id="O6" value="72.9" lower_limit="65.5" upper_limit="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1380</p_value>
            <method>McNemar</method>
            <param_type>Difference in Specificity (%)</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Specificity (%)</param_type>
            <param_value>28.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.7</ci_lower_limit>
            <ci_upper_limit>37.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Specificity (%)</param_type>
            <param_value>50.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.0</ci_lower_limit>
            <ci_upper_limit>59.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy: Percentage of True Positive and True Negative Among All Lesions</title>
        <description>Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>259 participants in the ITD population</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy: Percentage of True Positive and True Negative Among All Lesions</title>
          <description>Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.
Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.</description>
          <population>259 participants in the ITD population</population>
          <units>Percent true positive and negative lesio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Total lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="259"/>
                <count group_id="O5" value="259"/>
                <count group_id="O6" value="259"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="259"/>
                <count group_id="O4" value="259"/>
                <count group_id="O5" value="259"/>
                <count group_id="O6" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" lower_limit="50.3" upper_limit="62.4"/>
                    <measurement group_id="O2" value="78.0" lower_limit="72.9" upper_limit="83.0"/>
                    <measurement group_id="O3" value="45.6" lower_limit="39.5" upper_limit="51.6"/>
                    <measurement group_id="O4" value="79.5" lower_limit="74.6" upper_limit="84.5"/>
                    <measurement group_id="O5" value="19.3" lower_limit="14.5" upper_limit="24.1"/>
                    <measurement group_id="O6" value="81.5" lower_limit="76.7" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Accuracy (%)</param_type>
            <param_value>21.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.1</ci_lower_limit>
            <ci_upper_limit>29.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Accuracy (%)</param_type>
            <param_value>34.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.3</ci_lower_limit>
            <ci_upper_limit>40.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>McNemar</method>
            <param_type>Difference in Accuracy (%)</param_type>
            <param_value>75.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>67.9</ci_lower_limit>
            <ci_upper_limit>83.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Predictive Value [PPV]: Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound</title>
        <description>Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up.
Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 259 ITD participants, the overall number of participants (lesions) assessed as malignant varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Value [PPV]: Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound</title>
          <description>Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up.
Calculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.</description>
          <population>Among the 259 ITD participants, the overall number of participants (lesions) assessed as malignant varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
          <units>Percent positive lesions by ultrasound</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Positive lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="128"/>
                <count group_id="O6" value="147"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Positive lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="128"/>
                <count group_id="O6" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" lower_limit="43.4" upper_limit="62.1"/>
                    <measurement group_id="O2" value="71.5" lower_limit="64.2" upper_limit="78.9"/>
                    <measurement group_id="O3" value="39.6" lower_limit="30.3" upper_limit="48.9"/>
                    <measurement group_id="O4" value="78.9" lower_limit="71.5" upper_limit="86.4"/>
                    <measurement group_id="O5" value="14.8" lower_limit="8.7" upper_limit="21.0"/>
                    <measurement group_id="O6" value="74.1" lower_limit="67.1" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Predictive Value [NPV]: Percentage of True Negative Lesions Among All Benign Lesions Per Ultrasound</title>
        <description>Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 259 ITD participants, the number of participants (lesions) assessed as benign varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Value [NPV]: Percentage of True Negative Lesions Among All Benign Lesions Per Ultrasound</title>
          <description>Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
True negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.</description>
          <population>Among the 259 ITD participants, the number of participants (lesions) assessed as benign varied based on the evaluation of the UE-US and CE-US made by each off-site Reader.</population>
          <units>Percent negative lesions by ultrasound</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Negative lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="131"/>
                <count group_id="O6" value="112"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Negative lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="131"/>
                <count group_id="O6" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="51.2" upper_limit="67.0"/>
                    <measurement group_id="O2" value="86.1" lower_limit="79.8" upper_limit="92.4"/>
                    <measurement group_id="O3" value="49.7" lower_limit="41.8" upper_limit="57.6"/>
                    <measurement group_id="O4" value="80.0" lower_limit="73.5" upper_limit="86.5"/>
                    <measurement group_id="O5" value="23.7" lower_limit="16.4" upper_limit="30.9"/>
                    <measurement group_id="O6" value="91.1" lower_limit="85.8" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Wald Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Diagnosis of Malignant FLLs</title>
        <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 119 ITD participants with malignant lesions based on the truth standard, only 94 participants (lesions) were characterized as either hepatocellular carcinoma (HCC) lesions or metastatic lesions.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Diagnosis of Malignant FLLs</title>
          <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
          <population>Among the 119 ITD participants with malignant lesions based on the truth standard, only 94 participants (lesions) were characterized as either hepatocellular carcinoma (HCC) lesions or metastatic lesions.</population>
          <units>Malignant lesions</units>
          <param>Number</param>
          <units_analyzed>Malignant lesions to be characterized</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="94"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Malignant lesions to be characterized</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of HCC by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># HCC(Malignant) Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of Metastasis by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># Metastasis Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specific Diagnosis of Benign FLLs</title>
        <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Among the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <population>Among the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.</population>
        <group_list>
          <group group_id="O1">
            <title>Offsite Reader 1 UE-US</title>
            <description>Offsite Reader 1 UE-US assessment</description>
          </group>
          <group group_id="O2">
            <title>Offsite Reader 1 SonoVue CE-US</title>
            <description>Offsite Reader 1 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O3">
            <title>Offsite Reader 2 UE-US</title>
            <description>Offsite Reader 2 UE-US assessment</description>
          </group>
          <group group_id="O4">
            <title>Offsite Reader 2 SonoVue CE-US</title>
            <description>Offsite Reader 2 SonoVue CE-US assessment</description>
          </group>
          <group group_id="O5">
            <title>Offsite Reader 3 UE-US</title>
            <description>Offsite Reader 3 UE-US assessment</description>
          </group>
          <group group_id="O6">
            <title>Offsite Reader 3 SonoVue CE-US</title>
            <description>Offsite Reader 3 SonoVue CE-US assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Specific Diagnosis of Benign FLLs</title>
          <description>SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.
Among the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.
Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.</description>
          <population>Among the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.</population>
          <units>Benign lesions</units>
          <param>Number</param>
          <units_analyzed>Benign lesions to be characterized</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Benign lesions to be characterized</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="91"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of Hemangioma by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># Hemangioma Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of Focal nodular hyperplasia by Truth Standard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>#Focal nodular hyperplasia Correctly Characterized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter-reader Agreement</title>
        <description>Kappa statistic based on assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately and computation for the percentage agreement within two categories: &quot;3 out of 3 readers agree&quot; and &quot;2 out of 3 readers agree&quot;.</description>
        <time_frame>24 hours to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>UE-US</title>
            <description>UE-US Inter-reader agreement</description>
          </group>
          <group group_id="O2">
            <title>CE-US</title>
            <description>CE-US Inter-reader agreement</description>
          </group>
        </group_list>
        <measure>
          <title>Inter-reader Agreement</title>
          <description>Kappa statistic based on assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately and computation for the percentage agreement within two categories: &quot;3 out of 3 readers agree&quot; and &quot;2 out of 3 readers agree&quot;.</description>
          <units>Percentage of agreement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Agreement: All 3 off-site readers agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Agreement: 2 out of 3 off-site readers agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                    <measurement group_id="O2" value="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored from the time of signing the Informed Consent Form through 7 days after SonoVue administration.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a patient or a clinical trial subject administered a medicinal product and that did not necessarily have to have a causal relationship with the use of the product. Any patient who received SonoVue is in the Safety Population.
Of 353 patients who started the study, 13 had &quot;No study drug administered&quot; and are not included and 340 received SonoVue and are included in the Safety Population.
All AEs were categorized using MedDRA 12.1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Population</title>
          <description>Interventions included SonoVue administration, unenhanced and SonoVue-enhanced ultrasound and definitive truth standard diagnosis.
Any patient who received SonoVue, training or efficacy phase, regardless of availability of ultrasonography or truth standard, is included in the Safety Population.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Basophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results may be presented at scientific symposia or published in a peer-review journal after review by sponsor in accordance with the guidelines set forth in the applicable publication or financial agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Luigia Storto, MD Executive Director X-Ray and Ultrasound Medical Affairs</name_or_title>
      <organization>Bracco Diagnostics Inc.</organization>
      <phone>(609) 514-2200</phone>
      <email>MariaLuigia.Storto@diag.bracco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

